alferminogene tadenovec
Gene therapyexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
3
Phase 3
5
Phase 4
0
Earliest trial started Oct 1, 2001 (NCT00346437)
Timeline
Indications
Mechanism of action
- Fibroblast growth factor 4Supplementation
FGF4 supplementation
Chemistry & pharmacology
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL2107843 ↗
Also known as
- ad5fgf-4
- ad5fgf-4
- adf5fgf-4
- alferminogene tadenovec
- alferminogene tadenovec
- alferminogene tadenovec
- generx
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT02928094 | Phase 3 | Sep 1, 2017 | Angionetics Inc., Huapont Life Sciences |
| NCT01550614 | Phase 3 | Mar 1, 2012 | Advanced Biosciences Research, Gene Biotherapeutics, Inc. |
| NCT00438867 | Phase 3 | May 1, 2007 | Gene Biotherapeutics, Inc. |
| NCT00185263 | Phase 2/Phase 3 (Phase 3) | Mar 1, 2002 | Gene Biotherapeutics, Inc. |
| NCT00346437 | Phase 2/Phase 3 (Phase 3) | Oct 1, 2001 | Gene Biotherapeutics, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Gene Biotherapeutics, Inc. | For profit | 4 | 4 | 1 | 2001 |
| Advanced Biosciences Research | For profit | 1 | 0 | 1 | 2012 |
| Angionetics Inc. | For profit | 1 | 1 | 1 | 2017 |
| Huapont Life Sciences | For profit | 1 | 0 | 1 | 2017 |
4 organizations
Page 1 / 1